 SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 GLOBE NEWSWIRE -- I-Mab the Company Nasdaq: IMAB, a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. Kosdaq:298380, hereafter ABL, a South Korean biotech specializing in bispecific antibody technology, jointly announced that the U.S. Food and Drug Administration FDA has approved the Investigational New Drug IND application for initiating phase 1 trial for bispecific antibody TJ-CD4BABL111. The phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics PK and pharmacodynamics PD of TJ-CD4BABL111 in advanced or metastatic solid tumors. 